A3 receptor agonist modulates IL-1ß hippocampus levels in a rat model of neuropathic pain
Clin. biomed. res
;
42(2): 128-134, 2022.
Article
in English
| LILACS
| ID: biblio-1391544
ABSTRACT
Introduction:
Considering the lack of specific treatments for neuropathic pain, this study aimed to evaluate the effect of a single dose of adenosine A3 receptor IB-MECA on inflammatory and neurotrophic parameters in rats subjected to a neuropathic pain model.Methods:
64 adult male Wistar rats were used. Neuropathic pain was induced by chronic constriction injury (CCI) of the sciatic nerve and the treatment consisted of a 0.5 µmol/kg dose of IB-MECA, a selective A3 adenosine receptor agonist, dissolved in 3% DMSO; vehicle groups received DMSO 3% in saline solution, and morphine groups received 5 mg/kg. Cerebral cortex and hippocampus IL-1ß, BDNF, and NGF levels were determined by Enzyme-Linked Immunosorbent assay.Results:
The main outcome was that a single dose of IB-MECA was able to modulate the IL-1ß hippocampal levels in neuropathic pain induced by CCI and the DMSO increased IL-1ß and NGF hippocampal levels in sham-operated rats. However, we did not observe this effect when the DMSO was used as vehicle for IB-MECA, indicating that IB-MECA was able to prevent the effect of DMSO.Conclusions:
Considering that the IL-1ß role in neuropathic pain and the contributions of the hippocampus are well explored, our result corroborates the relationship between the A3 receptor and the process of chronic pain maintenance.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Neuralgia
Type of study:
Prognostic study
Limits:
Animals
Language:
English
Journal:
Clin. biomed. res
Journal subject:
Medicine
Year:
2022
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Universidade Federal do Rio Grande do Sul/BR
Similar
MEDLINE
...
LILACS
LIS